甲基化
DNA甲基化
生物标志物
表观遗传学
结直肠癌
癌症
亚硫酸氢盐测序
癌症研究
医学
发起人
肿瘤科
诊断生物标志物
生物
基因
内科学
基因表达
遗传学
作者
Keivan Moradi,Esmaeil Babaei,Nayebali Rezvani,Reza Safaralizadeh,Homayoon Bashiri,Mohammad Ali Hosseinpour Feizi
出处
期刊:PubMed
日期:2020-05-24
卷期号:57 (2): 166-171
被引量:3
标识
DOI:10.4103/ijc.ijc_542_18
摘要
Despite the advances in screening during the past decades, colorectal cancer (CRC) still is a leading cause of cancer deaths worldwide. Therefore, the development of new diagnostic methods is necessary.The aim of this study was to compare methylation changes of SRY-Box 21 (SOX21) gene promoter in tumor tissues and their normal adjacent mucosa in patients with CRC and to examine the relationship between the methylation levels and demographic/clinicopathological factors.A total of 41 CRC patients participated in the present study. After the extraction of DNA and bisulfite treatment of the samples, the methylation levels were determined by using the MethyLight method.Two-sided Mann-Whitney U test was used to compare the median level of methylation in tumor tissues and their adjacent normal mucosa.The methylation rates in tumor tissue samples were significantly higher compared to their adjacent normal mucosa (P < 0.0001). No association between demographic/clinicopathological factors and methylation status observed in tumor tissues. A receiver operating characteristics curve was constructed and tissue samples exhibited a sensitivity of 80.5% and specificity of 97.6% for SOX21 promoter methylation.The results of this study indicated the high potential of SOX21 gene promoter methylation as a candidate noninvasive diagnostic biomarker in stool and plasma of colorectal cancer patients. However, further studies with larger sample sizes are required to evaluate the specific role of SOX21 methylation as a biomarker for early detection of CRC.
科研通智能强力驱动
Strongly Powered by AbleSci AI